This information was published on 2024-12-13T00:06:20 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2480053 (IR 1807645) |
| (220) |
12 Jul 2024
|
| (511) (510) |
Class 5
Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes. Class 42 Research and development in the pharmaceutical and biotechnology fields. Class 45 Licensing of intellectual property in the field of biotechnology. |
| (540) | BIRCLERZI |
| (550) | Word |
| (730) |
Prothena Biosciences Limited
|
Find out more about publications on the About page.